| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 17.93 | 30.8% |
| Total Income | 17.93 | 30.8% |
| Expenditure | 20.11 | 38.2% |
| PBT | -2.81 | 242.7% |
| Net Profit | -2.81 | 242.7% |
| OPM | -12.18% | 6.11pp |
| NPM | -15.65% | 9.68pp |
| EPS | -0.06 | 100.0% |
Cosmos Health Reports Q1 2026 Revenue Up 31% to $17.9M
22 May 2026 · 22 May, 7:06 pm
Summary
Cosmos Health reported a record Q1 revenue of $17.93 million, a 30.7% increase compared to Q1 2025. The company's adjusted revenue grew by 34.2% year-over-year. Total liabilities decreased by $4.51 million, and stockholders' equity increased by $1.40 million. Adjusted EBITDA was near breakeven, and the company is focused on sustaining momentum into Q2 2026 with U.S. expansion plans.
Key Highlights
- 1
Cosmos Health achieved a record Q1 revenue of $17.93 million, representing a 30.7% increase from $13.71 million in Q1 2025.
- 2
Adjusted revenue increased by 34.2% year-over-year to $18.40 million, reflecting a $470,601 sales discount reversal.
- 3
Total liabilities decreased by $4.51 million, or 9.6%, to $42.54 million as of March 31, 2026.
- 4
Stockholders' equity increased by $1.40 million, or 7.6%, to $19.83 million as of March 31, 2026.
- 5
Adjusted EBITDA was near breakeven at ($229,596) in Q1 2026, as increased revenue was offset by higher expenses related to global growth initiatives.
- 6
The company's liabilities-to-assets ratio improved to 68.2% from 71.9% at year-end 2025.
- 7
Record momentum is expected to continue into Q2 2026 with U.S. expansion actively underway.
Management Comments
Greg Siokas
Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division — record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories. This momentum is continuing into Q2 2026, and we are focused on sustaining it well beyond this year. We believe Cosmos Health is entering a new phase of growth, driven by strategic investments across our organization — in personnel, facilities, infrastructure, technology, and AI-driven efficiencies — to support our global expansion plans, strengthen our R&D pipeline, and build the foundation for long-term sustainable value creation. A key pillar of this growth is our entry into the lucrative U.S. nutraceuticals market through the 18 Series platform. Adjusted EBITDA is near breakeven, and we expect it to turn positive as our growth investments drive meaningful returns and revenues continue to scale. At the same time, we have been disciplined in managing our balance sheet. We reduced total liabilities by $4.5 million in a single quarter, a 9.6% reduction, driven by a substantial reduction in convertible note and credit facility balances. Meanwhile, stockholders' equity increased by 7.6%, our liabilities-to-assets ratio improved by 370 basis points, and our liquidity position remains solid, with $4.3 million in liquid assets including cash of $2.2 million, to support our growth plans. Q1 2026 is an early indication of what we believe will be a period of significant growth for Cosmos Health, and we look forward to updating our shareholders as this story continues to unfold.”
Informational and educational content only. Not investment advice.